Bold calls on misunderstood and mispriced names.
Names that resolved or aged out. Stock-price movement, approximate.
+7×
Jun 2024 @ ~$2 → Jan 2026 @ ~$14
”Ventyx is well-positioned to reverse its fortunes in 2025. It's fully funded to deliver on three clinical trials, including a high-profile obesity readout... Sanofi has its toe in the water and could take the full plunge on VTX3232. It's a name investors should have on their radar.
Encode Coverage, Sept 2024
+7×
Oct 2019 @ $8.35 → Apr 2026 @ ~$57
”We believe XEN1101 has an excellent chance of success in X-TOLE, given it's a next-gen Kv7 agonist built off the same scaffold as FDA-approved AED ezogabine and the positive pharmacodynamic TMS data generated in their Ph1b study.
Encode Coverage, Mar 2021
+43×
Jan 2024 @ ~$2 → Apr 2026 @ ~$83
”Like most microcap biotechs, Bright Minds had a bumpy last few years, but when we saw the recent investor excitement around Longboard and their 5HT2c product, we thought it was a speculative name worth revisiting.
Encode Coverage, Jan 2024
Our latest notes, newest first.
$MSLE
$TARA
$EQ
$TARA
